Henry Schein (HSIC) Q2 2026 earnings review
Value Creation Initiatives Ignite Margin Expansion and Guidance Raise
Henry Schein delivered a strong second quarter, proving that its aggressive KKR-backed value creation and restructuring initiatives are bearing fruit. Internal sales growth accelerated to 4.6%, but the real story was the bottom line: Non-GAAP EPS surged 15.5% YoY to $1.27, beating expectations. By optimizing pricing, indirect procurement, and product mix, the company reversed the gross margin pressures that plagued it in 2025. With solid momentum across most dental and medical segments, management confidently raised full-year guidance for sales, Adjusted EBITDA, and EPS.
🐂 Bull Case
The margin degradation seen in 2025 from lower glove pricing and heavy promotions has been structurally fixed. Gross margin expanded by nearly 50 basis points YoY in Q2, driving operating leverage.
Global Dental Merchandise grew 9.7% overall and 5.9% internally. The company continues to successfully capture market share and wallet share post-cyber incident.
🐻 Bear Case
U.S. Dental Equipment sales turned negative (-1.1% YoY). If high interest rates and macro uncertainty are causing practices to delay large investments, this high-ticket segment could drag on H2 results.
Despite higher net income, Year-to-Date Operating Cash Flow fell to $145M from $157M the prior year, primarily due to working capital builds in inventory and accounts receivable.
⚖️ Verdict: 🟢
Bullish. The strategic pivot toward higher-margin software/specialty products and aggressive cost optimization is visibly working. The broad guidance raise signals management's high confidence in the second-half trajectory.
Key Themes
Value Creation Plan Delivering Real Leverage
Accelerating. The $200M+ margin improvement program initiated last year with KKR's input is visibly dropping to the bottom line. Gross Profit grew 8.4% against a 6.7% sales increase, expanding gross margins to 31.8% (up from 31.4% in 25Q2). The combination of value pricing, back-office consolidation, and corporate brand penetration drove Adjusted EBITDA up 12.5% YoY to $288 million.
Global Technology as the High-Margin Engine
Stable and strong. The Global Technology segment delivered 9.1% internal growth in Q2. Building on prior quarters' momentum of 20%+ growth in cloud subscribers and the integration of AI tools for clinical workflows, this software-as-a-service model remains the most vital driver for structurally improving Henry Schein's consolidated margin profile.
Market Share Gains in Core Distribution
Accelerating. Global Dental Merchandise posted impressive 5.9% internal growth. This validates management's prior assertions that the aggressive sales campaigns launched after the 2023 cyber incident not only won back lost customers but successfully captured permanent market share from competitors, particularly among growing DSOs (Dental Support Organizations).
U.S. Dental Equipment Declines
Reversing. In stark contrast to merchandise, U.S. Dental Equipment sales fell 1.1% YoY (0.0% internal growth). Equipment sales act as a barometer for dental practice sentiment. This decline suggests that higher borrowing costs and macroeconomic uncertainty are causing U.S. dentists to delay large capital expenditures and facility upgrades.
Medical Segment Recovers
Reversing. Following a soft 26Q1 that was dragged down by a weak flu season and lower diagnostic test demand, the Global Medical segment rebounded with 3.9% internal growth in Q2. This indicates a normalization of patient traffic and underlying stability in the physician and home care channels.
Working Capital Pressuring Cash Flow
Decelerating. Despite strong earnings growth, Year-to-Date Operating Cash Flow decreased YoY to $145 million (down from $157 million). This was driven by a heavier build in Accounts Receivable (a $116 million use of cash) and Inventory (a $49 million use of cash). While common during growth acceleration, this dynamic requires monitoring to ensure collections remain healthy.
Other KPIs
Accelerating. Driven by 3.2% internal growth and a 3.4% boost from acquisitions. This segment, containing high-margin implants and biomaterials, remains central to the BOLD+1 mix-shift strategy. Its steady expansion helps offset commoditization in basic consumables.
Stable. The company remains aggressive with its capital return strategy, buying back 2.6 million shares in Q2 (totaling $325M YTD). With $455 million still authorized, management continues to leverage its balance sheet to support EPS growth.
Guidance
Accelerating. Raised from the prior range of $5.23 to $5.37. The new midpoint ($5.34) implies roughly 7.4% growth over FY2025's $4.97. This reflects strong operational leverage and the early realization of value-creation savings.
Accelerating. Upgraded from the previous target of 3% to 5%. Given that YTD sales growth is already 6.5%, this implies a slight deceleration in the second half due to tougher year-over-year comparables, but remains a materially stronger outlook than initial expectations.
Accelerating. Upgraded from 'mid-single-digits'. Underscores management's confidence that gross margin improvements and SG&A restructuring are permanent structural upgrades to the P&L rather than one-time benefits.
Key Questions
U.S. Dental Equipment Weakness
U.S. Dental Equipment sales turned negative this quarter. Is this a temporary timing issue with practice builds, or a broader signal that macroeconomic pressures and high interest rates are causing dentists to shelve large capital projects?
Working Capital Normalization
Year-to-date operating cash flow is trailing last year despite higher net income, primarily due to AR and inventory builds. Should we expect a major working capital release and cash flow spike in the second half of 2026?
Value Creation Run-Rate
With gross margins already expanding nicely in Q2, how much of the targeted $125 million run-rate savings from the value creation initiatives is currently reflected in the P&L, and how much incremental benefit is still to come in H2?